Search clinical trials for: MRG002

Total 62 results

Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.

Locally Advanced Gastric Cancer | Metastatic HER2 Positive Gastroesophageal Junction Cancer

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors

Advanced Solid Tumor

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Advanced or Metastatic Biliary Tract Cancer

China
Shanghai Miracogen Inc.

Not yet recruiting

A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

Non-small- Cell Lung Cancer (NSCLC)

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Metastatic Urothelial Carcinoma | Locally Advanced Urothelial Cancer

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Advanced or Metastatic Breast Cancer

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Advanced Solid Tumors | Advanced or Metastatic Gastric Cancer | Advanced or Metastatic Gastroesophageal Junction Cancer

United States
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

Breast Cancer With Liver Metastases

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.

Advanced Malignant Solid Tumors

China
Shanghai Miracogen Inc.

Recruiting

Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

China
Shanghai Miracogen Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

China
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Compare the Pharmacokinetics of BR4002 and BR4002-1 in Healthy Volunteers

Dementia Alzheimers

Korea, Republic of
Shanghai Miracogen Inc.

Recruiting

A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors

Advanced Solid Tumors

China
Shanghai Miracogen Inc.

Completed

A Study of MRG003 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Shanghai Miracogen Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.

Advanced or Metastatic Gastric Cancer | Advanced or Metastatic Gastroesophageal Junction Carcinoma

China
Shanghai Miracogen Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Advanced or Metastatic Biliary Tract Cancer

China
Guy's and St Thomas' NHS Foundation Trust
King's College London

Recruiting

The MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19 (MONACO)

Covid19 | Pulmonary Fibrosis | Interstitial Lung Disease

United Kingdom
RinuaGene Biotechnology Co., Ltd.

Not yet recruiting

A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3

Cervical Intraepithelial Neoplasia Grade 2/3 | Human Papillomavirus Associated Intraepithelial Neoplasia | Human Papillomavirus Type 16 Infection | Human Papillomavirus Type 18 Infection
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Recruiting

The Study of Single Dose Administration of GR2002 Injection in Chinese Health Volunteers

Asthma

China
Shaanxi Micot Technology Limited Company

Terminated

MT1002 Phase II Study in ACS Patients With PCI

Acute Coronary Syndrome

United States
Gadeta B.V.

Active, not recruiting

A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
4D pharma plc
ICON plc; Labcorp Drug Development Inc

Withdrawn

Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's

Idiopathic Parkinson Disease
Prothena Biosciences Limited
Hoffmann-La Roche

Completed

Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease

Parkinson's Disease

United States
Prothena Biosciences Limited
Hoffmann-La Roche

Completed

Single Ascending Dose Study of PRX002 in Healthy Subjects

Parkinson's Disease

United States
Hoffmann-La Roche
Prothena Biosciences Limited

Active, not recruiting

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease (PASADENA)

Parkinson's Disease

United States, Spain, France, Germany, Austria
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Evaluate the Pharmacokinetics and Safety Between Single Administration of "BR6002" and Coadministration of "BR6002A" and "BR6002B" Under Fasting Conditions in Healthy Adult Volunteers

Gastric or Duodenal Ulcers

Korea, Republic of
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Evaluate the Pharmacokinetics and Safety Between Single Administration of "BR6002" and Coadministration of "BR6002A" and "BR6002B" Under Fed Conditions in Healthy Adult Volunteers

Gastric or Duodenal Ulcer

Korea, Republic of
Shaanxi Micot Technology Limited Company

Terminated

Evaluate the Effects of Renal Impairment on the Pharmacokinetics and Pharmacodynamics

ACS - Acute Coronary Syndrome

United States
Shaanxi Micot Technology Limited Company

Completed

Single Ascending Dose Trial to Evaluate the Safety, Tolerability, PK, and PD of MT1002 for Injection

Healthy

United States
CoMentis

Terminated

Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers

Diabetic Foot Ulcers

United States
Genzyme, a Sanofi Company

Completed

A Study of RG-012 in Subjects With Alport Syndrome

Alport Syndrome

United States
Huashan Hospital

Not yet recruiting

Evaluation of the Safety, Tolerability and Efficacy of Gene Therapy Drug for Late Onset Pompe Disease (LOPD)

Pompe Disease (Late-onset)

China
Laboratoires Genévrier
Institut National de la Santé Et de la Recherche Médicale, France; Hôpital...

Terminated

Efficacy and Tolerance of Cellularised LG002 Versus Uncellularised LG002 in the Treatment of Severe Burns Injuries

Burns

France
Shanghai Refreshgene Technology Co., Ltd.

Recruiting

Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular Degeneration

China
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of GR2002 Injection in Patients With Atopic Dermatitis.

Atopic Dermatitis

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

United States, China
Metagone Biotech Inc.

Completed

Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment With Solid Tumor

Solid Tumor

Taiwan
Zhen-Yu Ding

Recruiting

DC Combined With ICIs in the Treatment of Advanced Lung Cancer Resistant to ICIs

Lung Cancer

China
CSL Behring

Completed

Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis

Cystic Fibrosis

Bulgaria, Hungary, Poland, United Kingdom
Movetis

Completed

Study of Efficacy of a Vasopressin 2 Receptor Antagonist M0002 for Treatment of Ascites in Cirrhotic Subjects With Hypo- or Normonatraemia

Cirrhotic Ascites
Shanghai Miracogen Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Recurrent or Metastatic Nasopharyngeal Carcinoma

China
Mylan Pharma UK Ltd.

Completed

An Open Study to Assess the Robustness of the CRC749 Inhaler

Asthma | COPD

United Kingdom
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Advanced Breast Cancer | Metastatic Breast Cancer

China
Novartis Pharmaceuticals

Completed

Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma

Metastatic Renal Cell Carcinoma | Metastatic Melanoma

United States
Nanfang Hospital, Southern Medical University

Not yet recruiting

First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors

Advanced Solid Tumors

China
Chulalongkorn University

Completed

2940nm Er:YAG Laser Versus Benzoyl Peroxide Gel for the Treatment of Inflammatory Acne

Acne Vulgaris

Thailand
Tong Lee
National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)

Completed

PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)

Cocaine Dependence | Methamphetamine Dependence

United States
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Advanced or Metastatic Urothelium Cancer

China
Yuhan Corporation

Completed

Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers.

Healthy Adult Volunteers

Korea, Republic of

3

Subscribe